Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines

OncoImmunology

Volumn 6, Issue 3, 2017, Pages

  Klein, Christian ^a   Waldhauer, Inja ^a   Nicolini, Valeria G ^a   Freimoser Grundschober, Anne ^a   Nayak, Tapan ^b   Vugts, Danielle J ^c   Dunn, Claire ^a   Bolijn, Marije ^c   Benz, Jörg ^b   Stihle, Martine ^b   Lang, Sabine ^a   Roemmele, Michaele ^a   Hofer, Thomas ^a   van Puijenbroek, Erwin ^a   Wittig, David ^a   Moser, Samuel ^a   Ast, Oliver ^a   Brünker, Peter ^a   Gorr, Ingo H ^d   Neumann, Sebastian ^b   de Vera Mudry, Maria Cristina ^b   Hinton, Heather ^a   Crameri, Flavio ^b   Saro, Jose ^a   Evers, Stefan ^a   Gerdes, Christian ^a   Bacac, Marina ^a   van Dongen, Guus ^c   Moessner, Ekkehard ^a   Umaña, Pablo ^a   more..

^a Roche Innovation Center Zurich   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ROCHE INNOVATION CENTER MUNICH   (Germany)

Author keywords

Antibody; CEA; CEACAM5; IL 2; IL2v; Immunocytokine

Indexed keywords

ALDESLEUKIN; CD69 ANTIGEN; CERGUTUZUMAB AMUNALEUKIN; CETUXIMAB; FC RECEPTOR; IMGATUZUMAB; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; INTERLEUKIN 2 RECEPTOR GAMMA; PROGRAMMED DEATH 1 LIGAND 1; STAT5 PROTEIN; TRASTUZUMAB; ZIRCONIUM 89;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN BINDING; ANTIGEN STRUCTURE; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CD4 CD8 RATIO; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL ACTIVITY; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG EFFICACY; EFFECTOR CELL; ENDOTHELIUM CELL; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LUNG CANCER; NATURAL KILLER CELL; NONHUMAN; PROTEIN PHOSPHORYLATION; UPREGULATION;

EID: 85013488349     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1277306     Document Type: Article

References (67)

1. Malek TR, Yu A, Zhu L, Matsutani T, Adeegbe D, Bayer A. L. IL-2 family of cytokines in T regulatory cell development and homeostasis. J Clin Immunol 2008; 28:635-9; PMID:18726679; http://dx.doi.org/10.1007/s10875-008-9235-y
2. Kasprzak A, Olejniczak K, Przybyszewska W, Zabel M. Cellular expression of interleukin 2 (IL-2) and its receptor (IL-2R, CD25) in lung tumours. Folia Morphol (Warsz) 2007; 66:159-66; PMID:17985312
3. Waldmann TA. The biology of interleukin-2 and interleukin-15:implications for cancer therapy and vaccine design. Nat Rev Immunol 2006; 6:595-601; PMID:16868550; http://dx.doi.org/10.1038/nri1901
4. Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 2012; 12:180-90; PMID:22343569; http://dx.doi.org/10.1038/nri3156
5. Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2:Biology, Design and Application. Trends Immunol 2015; 36:763-77; PMID:26572555; http://dx.doi.org/10.1016/j.it.2015.10.003
6. Boyman O, Krieg C, Homann D, Sprent J. Homeostatic maintenance of T cells and natural killer cells. Cell Mol Life Sci 2012; 69:1597-608; PMID:22460580; http://dx.doi.org/10.1007/s00018-012-0968-7
7. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky A. Y. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005; 6:1142-51; PMID:16227984; http://dx.doi.org/10.1038/ni1263
8. D'Cruz LM, Klein L. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 2005; 6:1152-59; PMID:16227983; http://dx.doi.org/10.1038/ni1264
9. Maloy KJ, Powrie F. Fueling regulation:IL-2 keeps CD4+ Treg cells fit. Nat Immunol 2005; 6:1071-72; PMID:16239920; http://dx.doi.org/10.1038/ni1105-1071
10. Rosenberg SA, IL-2:the first effective immunotherapy for human cancer. J Immunol 2014; 192:5451-58; PMID:24907378; http://dx.doi.org/10.4049/jimmunol.1490019
11. Krieg C, Letourneau S, Pantaleo G, Boyman O. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells. Proc Natl Acad Sci U S A 2010; 107:11906-11; PMID:20547866; http://dx.doi.org/10.1073/pnas.1002569107
12. Kontermann RE. Antibody-cytokine fusion proteins. Arch Biochem Biophys 2012; 526:194-205; PMID:22445675; http://dx.doi.org/10.1016/j.abb.2012.03.001
13. Pasche N, Neri D. Immunocytokines:a novel class of potent armed antibodies. Drug Discov Today 2012; 17:583-90; PMID:22289353; http://dx.doi.org/10.1016/j.drudis.2012.01.007
14. Ortiz-Sanchez E, Helguera G, Daniels TR, Penichet ML. Antibody-cytokine fusion proteins:applications in cancer therapy. Expert Opin Biol Ther 2008; 8:609632; PMID:18407765; http://dx.doi.org/10.1517/14712598.8.5.609
15. Lode HN, Xiang R, Perri P, Pertl U, Lode A, Gillies SD, Reisfeld RA. What to do with targeted IL-2. Drugs Today (Barc) 2000; 36:321-36; PMID:12861355; http://dx.doi.org/10.1358/dot.2000.36.5.575044
16. Lode HN, Xiang R, Becker JC, Gillies SD, Reisfeld R A. Immunocytokines:a promising approach to cancer immunotherapy. Pharmacol Ther 1998; 80:277-92; PMID:9888698; http://dx.doi.org/10.1016/S0163-7258(98)00033-3
17. Tzeng A, Kwan BH, Opel CF, Navaratna T, Wittrup KD. Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proc Natl Acad Sci U S A 2015; 112:3320-3325; PMID:25733854; http://dx.doi.org/10.1073/pnas.1416159112
18. Zhu EF, Gai SA, Opel CF, Kwan BH, Surana R, Mihm MC, Kauke MJ, Moynihan KD, Angelini A, Williams RT, et al. Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell 2015; 27:489-501; PMID:25873172; http://dx.doi.org/10.1016/j.ccell.2015.03.004
19. Moynihan KD, Opel CF, Szeto GL, Tzeng A, Zhu E F, Engreitz JM, Williams RT, Rakhra K, Zhang MH, Rothschilds AM, et al. Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med 2016; 22(12):1402-10; PMID:27775706; http://dx.doi.org/10.1038/nm.4200
20. Ashraf SQ, Umana P, Mossner E, Ntouroupi T, Brunker P, Schmidt C, Wilding JL, Mortensen NJ, Bodmer WF. Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis. Br J Cancer 2009; 101:1758-68; PMID:19904275; http://dx.doi.org/10.1038/sj.bjc.6605355
21. Durbin H, Young S, Stewart LM, Wrba F, Rowan A J, Snary D, Bodmer WF. An epitope on carcinoembryonic antigen defined by the clinically relevant antibody PR1A3. Proc Natl Acad Sci U S A 1994; 91:4313-17; PMID:7514303; http://dx.doi.org/10.1073/pnas.91.10.4313
22. Wilkinson RW, Ross EL, Poulsom R, Ilyas M, Straub J, Snary D, Bodmer WF, Mather SJ. Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumors. Proc Natl Acad Sci U S A 2001; 98:10256-260; PMID:11517330; http://dx.doi.org/10.1073/pnas.181353498
23. Bacac M, Klein C, Umana P. CEA TCB:A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. Oncoimmunology 2016; 5:e1203498; PMID:27622073; http://dx.doi.org/10.1080/2162402X.2016.1203498
24. Lehmann S, Perera R, Grimm HP, Sam J, Colombetti S, Fauti T, Fahrni L, Schaller T, Freimoser-Grundschober A, Zielonka J, et al. In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing. Clin Cancer Res 2016; 22:4417-27; PMID:27117182; http://dx.doi.org/10.1158/1078-0432.CCR-15-2622
25. Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer W, Lehmann S, Hofer T, Hosse RJ, et al. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors. Clin Cancer Res 2016; 22:3286-97; PMID:26861458; http://dx.doi.org/10.1158/1078-0432.CCR-15-1696
26. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest 2005; 23:338-51; PMID:16100946; http://dx.doi.org/10.1081/CNV-58878
27. Oberst MD, Fuhrmann S, Mulgrew K, Amann M, Cheng L, Lutterbuese P, Richman L, Coats S, Baeuerle PA, Hammond SA. CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomas. MAbs 2014; 6:1571-84; PMID:25484061; http://dx.doi.org/10.4161/19420862.2014.975660
28. Peng L, Oberst MD, Huang J, Brohawn P, Morehouse C, Lekstrom K, Baeuerle PA, Wu H, Yao Y, Coats SR, et al. The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEA. PLoS One 2012; 7:e36412; PMID:22574157; http://dx.doi.org/10.1371/journal.pone.0036412
29. Bacac M, Fauti T, Sam J, Colombetti S, Weinzierl T, Ouaret D, Bodmer WF, Lehmann S, Hofer T, Hosse RJ, et al. A Novel Carcinoembryonic Antigen T Cell Bispecific Antibody (Cea Tcb) for the Treatment of Solid Tumors. Clin Cancer Res 2016; 22(13):3286-97; PMID:26861458; http://dx.doi.org/10.1158/1078-0432.CCR-15-1696
30. Govindan SV, Cardillo TM, Rossi EA, Trisal P, McBride WJ, Sharkey RM, Goldenberg DM. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug. Mol Pharm 2015; 12:1836-47; PMID:25402018; http://dx.doi.org/10.1021/mp5006195
31. Dabbs DJ, Sturtz K, Zaino RJ. The immunohistochemical discrimination of endometrioid adenocarcinomas. Hum Pathol 1996; 27:172-7; PMID:8617459; http://dx.doi.org/10.1016/S0046-8177(96)90371-8
32. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family:molecular biology and clinical perspectives. J Clin Lab Anal 1991; 5:344-66; PMID:1941355; http://dx.doi.org/10.1002/jcla.1860050510
33. Van Dongen GA, Huisman MC, Boellaard R, Harry Hendrikse N, Windhorst AD, Visser GW, Molthoff CF, Vugts DJ. 89Zr-immuno-PET for imaging of long circulating drugs and disease targets:why, how and when to be applied? Q J Nucl Med Mol Imaging 2015; 59:18-38; PMID:25517081
34. Rickert M, Wang X, Boulanger MJ, Goriatcheva N, Garcia KC. The structure of interleukin-2 complexed with its alpha receptor. Science 2005; 308:1477-80; PMID:15933202; http://dx.doi.org/10.1126/science.1109745
35. Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its alpha, beta, gammac receptors. Science 2005; 310:1159-63; PMID:16293754; http://dx.doi.org/10.1126/science.1117893
36. Hilton DJ, Watowich SS, Katz L, Lodish HF. Saturation mutagenesis of the WSXWS motif of the erythropoietin receptor. J Biol Chem 1996; 271:4699-708; PMID:8617735; http://dx.doi.org/10.1074/jbc.271.23.13754
37. Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, Kubbies M, Klein C, Umana P, Mossner E. Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions. Protein Eng Des Sel 2016; 29(10):457-66; PMID:27578889; http://dx.doi.org/10.1093/protein/gzw040
38. Merchant AM, Zhu Z, Yuan JQ, Goddard A, Adams CW, Presta LG, Carter P. An efficient route to human bispecific IgG. Nat Biotechnol 1998; 16:677-81 PMID:9661204; PMID:9661204; http://dx.doi.org/10.1038/nbt0798-677
39. Wild N, Andres H, Rollinger W, Krause F, Dilba P, Tacke M, Karl J. A combination of serum markers for the early detection of colorectal cancer. Clin Cancer Res 2010; 16:6111-6121; PMID:20798228; http://dx.doi.org/10.1158/1078-0432.CCR-10-0119
40. Clarke P, Mann J, Simpson JF, Rickard-Dickson K, Primus FJ. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res 1998; 58:1469-1477; PMID:9537250
41. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science 2006; 311:1924-27; PMID:16484453; http://dx.doi.org/10.1126/science.1122927
42. Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy:Mechanisms, response biomarkers, combinations. Sci Transl Med 2016; 8:328rv324; PMID:26936508; http://dx.doi.org/10.1126/scitranslmed.aad7118
43. Gerdes CA, Umana P. GA201:a novel humanized and glycoengineered anti-EGFR antibody–response. Clin Cancer Res 2014; 20; 1055; PMID:24536075; http://dx.doi.org/10.1158/1078-0432.CCR-13-2699
44. Spangler JB, Tomala J, Luca VC, Jude KM, Dong S, Ring AM, Votavova P, Pepper M, Kovar M, Garcia KC. Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms. Immunity 2015; 42:815-25; PMID:25992858; http://dx.doi.org/10.1016/j.immuni.2015.04.015
45. Levin AM, Bates DL, Ring AM, Krieg C, Lin JT, Su L, Moraga I, Raeber ME, Bowman GR, Novick P, et al. Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’. Nature 2012; 484:529-33; PMID:22446627; http://dx.doi.org/10.1038/nature10975
46. Charych DH, Hoch U, Langowski JL, Lee SR, Addepalli MK, Kirk PB, Sheng DW, Liu XF, Sims PW, VanderVeen LA, et al. NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, Marked Efficacy in Mouse Tumor Models. Clinical Cancer Research 2016; 22:680-90; PMID:26832745; http://dx.doi.org/10.1158/1078-0432.CCR-15-1631
47. Gillies SD, Lan Y, Hettmann T, Brunkhorst B, Sun Y, Mueller SO, Lo KM. A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity. Clin Cancer Res 2011; 17:3673-85; PMID:21531812; http://dx.doi.org/10.1158/1078-0432.CCR-10-2921
48. Gillessen S, Gnad-Vogt US, Gallerani E, Beck J, Sessa C, Omlin A, Mattiacci MR, Liedert B, Kramer D, Laurent J, et al. A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours. Eur J Cancer 2013; 49:35-44; PMID:22918078; http://dx.doi.org/10.1016/j.ejca.2012.07.015
49. Carmenate T, Pacios A, Enamorado M, Moreno E, Garcia-Martinez K, Fuente D, Leon K. Human IL-2 mutein with higher antitumor efficacy than wild type IL-2. J Immunol 2013; 190:6230-38; PMID:23677467; http://dx.doi.org/10.4049/jimmunol.1201895
50. Losey HC, Lopes JE, Dean RL, Flick H, Gomes M, Huff MR, Moroso RA, Sun L, Wang C, Waters JF, et al. Utilizing a selective agonist of the intermediate-affinity IL-2 receptor with an improved pharmacokinetic profile leads to an enhanced immunostimulatory response with reduced toxicity in mice, Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA). Cancer Res 2015 2001; 75(15 Suppl), Abstract nr 3158.
51. Sim GC, Liu C, Wang E, Liu H, Creasy C, Dai Z, Overwijk WW, Roszik J, Marincola FM, Hwu P, et al. IL-2 variant circumvents ICOS+ regulatory T cell expansion and promotes NK cell activation. Cancer Immunol Res 2016; PMID:27697858; http://dx.doi.org/10.1158/2326-6066.CIR-15-0195
52. Ghasemi R, Lazear E, Wang X, Arefanian S, Zheleznyak A, Carreno BM, Higashikubo R, Gelman AE, Kreisel D, Fremont DH, et al. Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy. Nat Commun 2016; 7:12878; PMID:27650575; http://dx.doi.org/10.1038/ncomms12878
53. Boyman O, Surh CD, Sprent J. Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease. Expert Opin Biol Ther 2006:6:1323-1331; PMID:17223740; http://dx.doi.org/10.1517/14712598.6.12.1323
54. Arenas-Ramirez N, Zou C, Popp S, Zingg D, Brannetti B, Wirth E, Calzascia T, Kovarik J, Sommer L, Zenke G, et al. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. Sci Transl Med 2016; 8:367ra166; PMID:27903862; http://dx.doi.org/10.1126/scitranslmed.aag3187
55. Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR, van Dongen GA. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005; 46:1898-1906; PMID:16269605
56. Ring AM, Lin JX, Feng D, Mitra S, Rickert M, Bowman GR, Pande VS, Li P, Moraga I, Spolski R, et al. Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat Immunol 2012; 13:1187-95; PMID:23104097; http://dx.doi.org/10.1038/ni.2449
57. Waldmann TA. The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes:implications for cancer therapy. Cancer Immunol Res 2015; 3:219-227; PMID:25736261; http://dx.doi.org/10.1158/2326-6066.CIR-15-0009
58. Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, Fleisher TA, Dubois SP, Perera LP, Stewart DM, et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. Journal of clinical oncology:official journal of the American Society of Clinical Oncology 2015; 33:74-82; PMID:25403209; http://dx.doi.org/10.1200/JCO.2014.57.3329
59. Otegbeye F, Mackowski N, Ojo E, De Lima M, Wald DN. The IL-15 Super-Agonist ALT-803 Promotes Superior Activation and Cytotoxicity of Ex Vivo Expanded NK Cells Against AML. Blood 2015; 126:3090.
60. Rosario M, Liu B, Kong L, Collins LI, Schneider SE, Chen X, Han K, Jeng EK, Rhode PR, Leong JW et al. The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. Clin Cancer Res. 2016; 22:596-608; PMID:26423796; http://dx.doi.org/10.1158/1078-0432.CCR-15-1419
61. Wong HC, Jeng EK, Rhode PR. The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity. Oncoimmunology 2013; 2:e26442; PMID:24404427; http://dx.doi.org/10.4161/onci.26442
62. Xu WX, Jones M, Liu B, Zhu XY, Johnson CB, Edwards AC, Kong L, Jeng EK, Han KP, Marcus WD, et al. Efficacy and Mechanism-of-Action of a Novel Superagonist Interleukin-15:Interleukin-15 Receptor alpha Su/Fc Fusion Complex in Syngeneic Murine Models of Multiple Myeloma. Cancer Res 2013; 73:3075-86; PMID:23644531; http://dx.doi.org/10.1158/0008-5472.CAN-12-2357
63. Miller JS, Cooley S, Holtan S, Arora M, Ustun C, Jeng E, Wong HC, Verneris MR, Wagner JE, Weisdorf DJ, et al. 'First-in-human' phase I dose escalation trial of IL-15N72D/IL-15R alpha-Fc superagonist complex (ALT-803) demonstrates immune activation with anti-tumor activity in patients with relapsed hematological malignancy. Blood 2015; 126:1957; http://dx.doi.org/10.1182/blood-2015-02-625574
64. Liu B, Kong L, Han K, Hong H, Marcus WD, Chen X, Jeng EK, Alter S, Zhu X, Rubinstein MP, et al. A novel fusion of ALT-803 (IL-15 Superagonist) with an antibody demonstrates antigen-specific antitumor responses. J Biol Chem 2016; 291(46):23869-881; PMID:27650494; http://dx.doi.org/10.1074/jbc.M116.733600
65. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014; 515:572-6; PMID:25428506; http://dx.doi.org/10.1038/nature14001
66. Lechner MG, Karimi SS, Barry-Holson K, Angell TE, Murphy KA, Church CH, Ohlfest JR, Hu P, Epstein AL. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J Immunother 2013; 36:477-89; PMID:24145359; http://dx.doi.org/10.1097/01.cji.0000436722.46675.4a
67. Schliemann C, Palumbo A, Zuberbuhler K, Villa A, Kaspar M, Trachsel E, Klapper W, Menssen HD, Neri D. Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood 2009; 113:2275-83; PMID:19005180; http://dx.doi.org/10.1182/blood-2008-05-160747